Odyssey bails on public listing as US IPO landscape stutters

finance.yahoo.com/news/odyssey-bails-public-listing-us-170357311.html

Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO).
The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO…

This story appeared on finance.yahoo.com, 2025-06-10 17:03:57.
The Entire Business World on a Single Page. Free to Use →